Literature DB >> 8527267

Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets.

J A Cooper1, S J Hill, S P Alexander, P C Rubin, E H Horn.   

Abstract

1. We have assessed the effects of adenosine receptor agonists and antagonists on collagen-induced 5-hydroxytryptamine (5-HT) release and cyclic AMP generation in human platelets. 2. 5'-N-ethylcarboxamidoadenosine (NECA) and CGS 21680 elicited accumulations of cyclic AMP with mean EC50 values of 2678 and 980 nM, respectively. The maximal response to CGS 21680 was approximately half that of the response to 10 microM NECA. 3. NECA and CGS 21680 inhibited collagen-induced 5-hydroxytryptamine release with mean EC50 values of 960 and 210 nM, respectively. The maximal response to CGS 21680 was approximately 25% of the response to 10 microM NECA. 4. The A1/A2a-selective adenosine receptor antagonist PD 115,199 was more potent as an inhibitor of NECA-elicited responses than the A1-selective antagonist DPCPX with calculated Ki values of 22-32 nM and > 10 microM, respectively. 5. In the presence of a cyclic AMP phosphodiesterase inhibitor, the effects of CGS 21680 on cyclic AMP accumulation and 5-HT release were enhanced to levels similar to those elicited by 10 microM NECA. In the absence of phosphodiesterase inhibition, CGS 21680 did not antagonise the effects of NECA. Furthermore, endogenous adenosine did not contribute to the effects of CGS 21680 when phosphodiesterase was inhibited. 6. We conclude that an A2a adenosine receptor appears to be involved in the NECA-elicited increases in cyclic AMP levels and inhibition of 5-HT release in human platelets.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8527267      PMCID: PMC1365026          DOI: 10.1111/j.1365-2125.1995.tb04533.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

2.  Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells.

Authors:  D van Calker; M Müller; B Hamprecht
Journal:  J Neurochem       Date:  1979-11       Impact factor: 5.372

3.  Effects of adenosine on levels of adenosine cyclic 3',5'-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation.

Authors:  R J Haslam; G M Rosson
Journal:  Mol Pharmacol       Date:  1975-09       Impact factor: 4.436

4.  Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour.

Authors:  S Heptinstall; J Bevan; S R Cockbill; S P Hanley; M J Parry
Journal:  Thromb Res       Date:  1980-10-15       Impact factor: 3.944

5.  Subclasses of external adenosine receptors.

Authors:  C Londos; D M Cooper; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  Measurement of circulating prostacyclin.

Authors:  R J Haslam; M D McClenaghan
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

7.  Effect of dipyridamole on human platelet behaviour.

Authors:  P R Emmons; M J Harrison; A J Honour; J R Mitchell
Journal:  Lancet       Date:  1965-09-25       Impact factor: 79.321

8.  5'-N-ethylcarboxamidoadenosine: a potent inhibitor of human platelet aggregation.

Authors:  N J Cusack; S M Hourani
Journal:  Br J Pharmacol       Date:  1981-03       Impact factor: 8.739

9.  Adenosine A2B-receptor-mediated cyclic AMP accumulation in primary rat astrocytes.

Authors:  M C Peakman; S J Hill
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

10.  A comparison of A2 adenosine receptor-induced cyclic AMP generation in cerebral cortex and relaxation of pre-contracted aorta.

Authors:  S P Alexander; A Losinski; D A Kendall; S J Hill
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

View more
  11 in total

1.  Characterization of the human brain putative A2B adenosine receptor expressed in Chinese hamster ovary (CHO.A2B4) cells.

Authors:  S P Alexander; J Cooper; J Shine; S J Hill
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  P2X1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice.

Authors:  Roxane Darbousset; Céline Delierneux; Soraya Mezouar; Alexandre Hego; Christelle Lecut; Isabelle Guillaumat; Markus A Riederer; Richard J Evans; Françoise Dignat-George; Laurence Panicot-Dubois; Cécile Oury; Christophe Dubois
Journal:  Blood       Date:  2014-08-22       Impact factor: 22.113

3.  Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.

Authors:  Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  Am J Pathol       Date:  2012-05-18       Impact factor: 4.307

Review 4.  A2 adenosine receptors and vascular pathologies.

Authors:  Hillary A Johnston-Cox; Milka Koupenova; Katya Ravid
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

5.  Adenosine and blood platelets.

Authors:  Hillary A Johnston-Cox; Katya Ravid
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

Review 6.  The resurgence of A2B adenosine receptor signaling.

Authors:  Carol M Aherne; Emily M Kewley; Holger K Eltzschig
Journal:  Biochim Biophys Acta       Date:  2010-05-28

Review 7.  Regulation of leukocyte function by adenosine receptors.

Authors:  Joel Linden
Journal:  Adv Pharmacol       Date:  2011

8.  Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction.

Authors:  Lauren J Murphree; Gail W Sullivan; Melissa A Marshall; Joel Linden
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 9.  P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window.

Authors:  C Y E Fung; Aaron J Marcus; M Johan Broekman; Martyn P Mahaut-Smith
Journal:  Trends Cardiovasc Med       Date:  2009-01       Impact factor: 6.677

10.  Pharmacological and biochemical characterization of purified A2a adenosine receptors in human platelet membranes by [3H]-CGS 21680 binding.

Authors:  K Varani; S Gessi; A Dalpiaz; P A Borea
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.